Pharmaron (03759) Report Interpretation

Overview

This conference-feedback update examines Pharmaron’s position in China’s CDMO market. Morgan Stanley argues that rising outsourcing, limited global small-molecule API capacity, expanding commercial capability and more diversified manufacturing locations support the company’s growth outlook.

Core views

Morgan Stanley identifies four persistent themes from its Global Healthcare Conference discussions on China CDMOs: rising outsourcing penetration, a chronic shortage of small-molecule capacity, demand for supply bases outside China, and AI-enabled drug discovery. It argues that tight global small-molecule API capacity is directing work toward leading Chinese CDMOs, specifically naming WuXi AppTec, Pharmaron and Asymchem. The effect is expected to be stronger for complex small molecules and advanced modalities, where Pharmaron is expanding capabilities in biologics, antibody-drug conjugates and peptides. The report’s central operating thesis is that Pharmaron’s project portfolio should shift materially toward later-stage and commercial contracts over the next three years. Its small-molecule API reactor capacity is planned to double from 1,200 cubic meters to 2,400 cubic meters by 2028, with the objective of reaching large-scale commercial production in the next few years. Morgan Stanley notes that utilization is currently described as “very high,” while raised guidance incorporates improving early-stage biopharma fundraising conditions and commercial backlog. The report also cites oral GLP-1 projects beyond Lilly’s orforglipron as part of Pharmaron’s integrated-project pipeline. Pharmaron is simultaneously building a more diversified manufacturing footprint. About 80% of capacity is expected to remain in China, while commercial-scale API capacity in Rhode Island and the UK addresses customer demand for regionalized supply. Through a joint venture, it also operates a Singapore drug-products site. Capital expenditure and acquisitions are expected to remain China-focused, and the recent Shaoxing expansion is characterized as a significant step-change. AI drug discovery is presented as a supportive but moderate contributor rather than the main growth driver: it represents about 5% of overall revenue and is concentrated in lab services. Morgan Stanley’s valuation case for the Hong Kong listing uses a DCF framework with a 10.5% WACC, 3.0% terminal growth rate, RMB:HKD exchange rate of 1.1 and an assumed A-H premium of about 28%. The report retains an Overweight rating and a HK$36.50 target price, versus a September 16 share price of HK$29.10, implying 25% upside.

Analysis framework

Morgan Stanley combines conference feedback on CDMO demand and capacity with Pharmaron’s capacity-expansion plans, project mix, utilization and geographic manufacturing footprint. It then values the Hong Kong-listed shares using discounted cash flow assumptions and an A-H share valuation relationship.

Methodology notes

• Valuation methodsDCF (Discounted Cash Flow)

  Discounted cash flow valuation

  The report derives its valuation using a DCF model with a 10.5% WACC and 3.0% terminal growth rate, translating the result for the Hong Kong listing using a RMB:HKD rate of 1.1 and an approximately 28% A-H premium.

• Industry AnalysisSupply-demand framework

  Global small-molecule API capacity and outsourcing supply-demand analysis

  Morgan Stanley links constrained global API manufacturing capacity to greater outsourcing demand for leading Chinese CDMOs, particularly in complex small molecules and advanced modalities.

Asset mapping & comparison

Structured mapping from thesis to named assets (strengths, weaknesses, peers, risks).

• Pharmaron (03759.HK)

  Primary covered Hong Kong-listed security; expected to benefit from tight small-molecule API capacity, outsourcing growth and a transition to commercial-scale projects.

  Strengths

  High utilization, planned doubling of API reactor capacity by 2028, integrated projects and expansion into biologics, ADCs and peptides.

  Weaknesses

  AI drug discovery remains a moderate contributor at about 5% of revenue.

  Comparison

  Morgan Stanley cites WuXi AppTec and Asymchem as other leading Chinese CDMOs benefiting from global capacity constraints; WuXi AppTec had over 4,000 cubic meters of capacity at end-2025.

  Risks

  Further overseas-site losses, delayed projects, longer order confirmation and booking cycles, weaker domestic competition conditions, and geopolitical or currency risks.

• Pharmaron (300759.SZ)

  A-share listing of the covered company referenced in the report’s valuation and rating-history materials.

  Strengths

  Linked to the same operating themes of commercial project transition and expanding small-molecule API capacity.

  Comparison

  The valuation framework assumes an approximately 28% A-H premium.

  Risks

  Firm overseas demand is identified as an upside factor if geopolitical pressure eases.

Key data

• Hong Kong share target priceHK$36.50Morgan Stanley target price for Pharmaron (3759.HK).
• Hong Kong share priceHK$29.10Closing price on September 16, 2026.
• Implied upside25%Upside to the HK$36.50 target price.
• Small-molecule API reactor capacity1,200 cubic meters to 2,400 cubic metersCapacity is expected to double by 2028.
• AI drug discovery revenue contribution~5% of overall revenuePrimarily associated with the lab services segment.
• China capacity share~80%Expected share of Pharmaron capacity remaining in China.
• DCF WACC / terminal growth10.5% / 3.0%Key valuation assumptions.

Impact & implications

The report argues that capacity expansion, high utilization and a move toward later-stage commercial work could allow Pharmaron to benefit from a structurally tight global small-molecule manufacturing market. Its Western and Singapore operations are positioned as responses to customers seeking diversified and regionalized supply chains.

Risks

• Further losses from overseas sites could weigh on results.
• Project delays and longer order-confirmation or booking cycles could slow growth.
• A deterioration in China’s domestic competitive landscape could pressure the business.
• Geopolitical and currency risks could affect overseas demand and operations.

What to watch

• Recovery in domestic orders as the biopharma fundraising environment improves.
• Overseas demand as geopolitical pressure eases.
• The mix and margins of later-stage and commercial orders.
• Contribution and margins from emerging business units.
• Progress in scaling small-molecule API capacity toward 2,400 cubic meters by 2028.